Skip to main content
Premium Trial:

Request an Annual Quote

Kailos Genetics Receives Investment From In-Q-Tel

NEW YORK (GenomeWeb) – Kailos Genetics said today that it has received a strategic investment from In-Q-Tel, a nonprofit that invests in technologies to support the mission of the US intelligence community.

Terms and financial details of the deal were not disclosed.

Kailos said it plans to use the investment in a partnership with In-Q-Tell to develop its next-generation sequencing laboratory and software for the benefit of the intelligence community.

Kailos was spun out of the HudsonAlpha Institute of Biotechnology in 2010 and offers NGS panels — both consumer-focused panels as well as ones that can be ordered by a physician — and cloud-based software.

Tom Gillespie, an investment partner at IQT, said in a statement that investing in Kailos and enabling further development of its technology would "provide valuable capabilities for both the public and private sector."

Kailos CSO Troy Moore added that the company is "excited to partner with IQT to continue our development of solutions for the identification of genetic materials."